By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • Health Topics
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • Health Topics
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Policy & Systems > Quality & Safety > South African regulator recalls Citro-Soda batches amid contamination fears
Quality & Safety

South African regulator recalls Citro-Soda batches amid contamination fears

GMJ
Last updated: 25/05/2026 17:59
By
GMJ Policy Desk
Share
4 Min Read
SAHPRA South African Health Products Regulatory Authority logo and Citro-Soda product recall announcement
South Africa's drug regulator SAHPRA has announced an urgent recall of specific Citro-Soda Regular batches due to potential contamination at a Johannesburg facility. The precautionary measure affects products from Adcock Ingram's Clayville manufacturing site. — Photo: Leonid Altman / Pexels
SHARE
🎧 Listen to this article3:57 min · 570 words · GMJ Audio

Updated 25/05/2026

Contents
  • Regulatory response to manufacturing concerns
  • Limited scope of safety action
    • Key takeaways
  • Frequently asked questions
    • Which Citro-Soda products are affected by the recall?
    • What type of contamination risk has been identified?
    • Should consumers stop using all Citro-Soda products?
2 min read|383 words

South Africa’s drug regulator has announced an urgent recall of specific batches of Citro-Soda Regular following potential contamination risks at a Johannesburg manufacturing facility. The South African Health Products Regulatory Authority (SAHPRA) confirmed the precautionary measure affects products manufactured at the Adcock Ingram Clayville facility, according to SAHPRA’s March 20, 2026 announcement.

Multiple batches
of Citro-Soda Regular recalled by SAHPRA due to contamination concerns

Regulatory response to manufacturing concerns

SAHPRA announced it will brief media on the recall following identification of potential contamination risks at the manufacturing site. The recall is being conducted as a precautionary measure to ensure patient safety, according to SAHPRA’s official statement.

The affected batches were produced at Adcock Ingram’s Clayville manufacturing facility in Johannesburg, as confirmed by SAHPRA. The regulatory authority has not disclosed the specific nature of the contamination risk or the total number of units affected by the recall.

Submit Your Paper
GMJ_Submit_Banner

Limited scope of safety action

The recall has been described by SAHPRA as limited in scope, affecting only specific batches rather than all Citro-Soda Regular products. This targeted approach suggests the contamination risk may be contained to particular production runs or time periods.

🎙️ Related Podcast Episodes
🎧 #3 Global Nestlé Infant Formula Recall: The Power of Modern Public Health in Practice | GMJ Official Podcast · 21m
🎧 #44 | GMJ Podcast | Infant Formula Contamination — Global Food Safety Failure and the Cereulide Outbreak · 21m
🎧 #12 | WHO and Global Regulators Promote Antibiotic Labelling to Combat Antimicrobial Resistance · 19m

Further details about pharmaceutical quality and safety measures are expected to be provided during SAHPRA’s media briefing.

The recall is being conducted as a precautionary measure following identification of potential contamination risks at the Adcock Ingram Clayville manufacturing facility.

— South African Health Products Regulatory Authority (SAHPRA), March 20, 2026

Key takeaways

  • SAHPRA has recalled specific batches of Citro-Soda Regular due to contamination concerns
  • The recall affects products manufactured at Adcock Ingram’s Clayville facility in Johannesburg
  • The action is described as precautionary and limited in scope to specific batches

Frequently asked questions

Which Citro-Soda products are affected by the recall?

The recall specifically affects Citro-Soda Regular products from certain batches manufactured at the Adcock Ingram Clayville facility, according to SAHPRA.

What type of contamination risk has been identified?

SAHPRA has not disclosed the specific nature of the contamination risk. More details are expected to be provided during the regulatory authority’s media briefing.

Should consumers stop using all Citro-Soda products?

The recall is limited to specific batches of Citro-Soda Regular only, according to SAHPRA. Consumers should check their product batch numbers and follow official guidance from healthcare authorities.

Source: SAHPRA to brief media on the recall of specified batches of Citro-Soda Regular amid safety concerns

Was this article helpful?

Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →

Related Coverage

Large AI Models in Healthcare Show Hidden Gaps Between Benchmark Success and Clinical RobustnessAug 21, 2026
Medicare Advantage Insurer Elevance Health Pays $342 Million to Settle Billing Dispute with CMSAug 21, 2026
Europe reports 949 avian flu cases in birds across 30 countries in first half of 2026Aug 21, 2026
Vegan, Gluten-Free, Cruelty-Free: What a Manufacturer's Declaration Is WorthAug 20, 2026
Explore more on this topic:🧭 Atrial Fibrillation hub🧭 Leukaemia hub🧭 Rheumatoid Arthritis hub
🔥 Most read this week
1High-Dose Zinc Supplements May Create Copper Deficiency, Warn Nutrition Experts
2Evidence-Based Hydration Protocol: How Much Fluid and Sodium Athletes Actually Need
3L-Theanine Improves Sleep Quality Without Drowsiness, Systematic Review Finds
4How Coffee Brewing Method Affects Cholesterol: The Science Behind Diterpenes and Filters
PG
Editorial oversight
Prof. Giorgi Pkhakadze, MD, MPH, PhD
Editor-in-Chief, GMJ News
Full profile →  ·  ORCID 0000-0001-7609-4515
Medical disclaimer. This article is health journalism intended for general information. It is not medical advice and is not a substitute for consultation with a qualified healthcare professional. Always seek your physician's advice regarding any medical condition.
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
📬 GMJ Health Digest
Evidence-based medical news, once a week. Free, no spam, unsubscribe anytime.
TAGGED:contaminationdrug recallpharmaceutical safetySAHPRASouth Africa
Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByGMJ Policy Desk
Follow:
GMJ Policy Desk is part of GMJ News, the newsroom of the Georgian Medical Journal (gmj.ge), published by the Public Health Institute of Georgia. Every article is editorially reviewed before publication.
Leave a Comment Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Large AI Models in Healthcare Show Hidden Gaps Between Benchmark Success and Clinical Robustness

Leading AI models in healthcare score high on standard benchmarks but fail…

UN Rights Chief Demands Independent Investigation into US Immigration Detention Deaths

The UN High Commissioner for Human Rights has called for independent investigations…

Medicare Advantage Insurer Elevance Health Pays $342 Million to Settle Billing Dispute with CMS

Elevance Health, a major Medicare Advantage insurer, has agreed to pay $342…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Comparison of fish oil oxidation levels and safety testing standards across commercial supplement productsIllustrative image · Photo by Pixabay on Pexels (Pexels License)
Pharmacy & PrescribingPolicy & SystemsPracticeQuality & Safety

Half of Commercial Fish Oil Supplements Exceed Oxidation Safety Limits—But Human Risk Remains Unclear

By
GMJ Practice Desk
25/07/2026
Hospital discharge data comparing insurance status among gunshot wound patientsIllustrative image · Photo by Markus Spiske on Unsplash (Unsplash License)
Data & NumbersGlobal HealthPolicy & SystemsQuality & SafetyResearch Digest

Uninsured Gunshot Wound Patients Discharged Faster From Florida Hospitals, Data Shows

By
GMJ Research Desk
13/08/2026
Comparison chart showing treatment response of bradykinin vs histamine-mediated angioedema to standard medicationsIllustrative image · More than makeup- Surgeon Cell Soldier turns moulage art into operational readiness (9245265).jpg by U.S. Army photo by Spc. Micheala Maldonado / Public domain via Wikimedia Commons (Public domain)
Pharmacy & PrescribingPolicy & SystemsPracticeQuality & Safety

ACE Inhibitors and Angioedema: Why Distinguishing Drug Types Matters for Treatment

By
GMJ Practice Desk
10/07/2026
FDA Vaccines and Related Biological Products Advisory Committee meeting room with advisers reviewing vaccine dataIllustrative image · Photo by Maksim Goncharenok on Pexels (Pexels License)
Clinical UpdatesPolicy & SystemsPracticeQuality & Safety

FDA Advisory Panel Endorses Moderna mRNA Flu Vaccine After Earlier Controversy

By
GMJ Practice Desk
12/07/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?